secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001104659-24-067544
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix cuts 13% of workforce, 37 jobs, to prioritize AXPAXLI
------------------------------------------------------------------------

- Board approved reduction in force of 37 employees (~13% of workforce), mainly in R&D and technical operations.
- Action taken to focus resources on AXPAXLI (axitinib intravitreal implant) for wet AMD clinical development.
- Expects total restructuring costs of $1.0 to $2.0 million for severance and related costs in Q2/Q3 2024.
- Reduction expected to be substantially completed in Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465924067544/0001104659-24-067544-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465924067544/tm2416236d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-067544

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer